GADOVIST PFS Price

Overview

Welcome to Dwaey, specifically on GADOVIST PFS page.
This medicine contains an important and useful components, as it consists of
Gadobutrolis available in the market in concentration

Name

Calcipotriene 0.005%

Precaution

Before using **Calcipotriene 0.005%**, it is essential to consult a healthcare provider to ensure its appropriateness for your condition, particularly in the following situations: - **Skin Sensitivity**: If the patient has sensitive skin, particularly if they have conditions like **eczema** or **psoriasis** in areas like the face or skin folds, it’s important to use **calcipotriene** with caution to prevent irritation or unwanted reactions. - **Hypercalcemia**: Calcipotriene is a form of vitamin D, and prolonged use may lead to elevated levels of calcium in the blood (**hypercalcemia**). Patients should be monitored for signs of high calcium levels, such as **nausea**, **vomiting**, **confusion**, or **fatigue**. - **Pregnancy and Breastfeeding**: **Calcipotriene** is categorized as **Category C** during pregnancy, which means it should only be used if the benefits outweigh the risks. It should be avoided on large areas of the skin during pregnancy or breastfeeding, as the potential for systemic absorption is higher. - **Avoiding Overuse**: Excessive or prolonged use of Calcipotriene on large areas can increase the risk of systemic absorption and side effects such as hypercalcemia, so it should be used exactly as directed. - **Sensitive Areas**: Care should be taken when applying to sensitive areas like the **face**, **genitals**, or **underarms**, as the skin is more prone to irritation, and the drug may be more easily absorbed in these regions.

Indication

**Calcipotriene 0.005%** is primarily used to treat **psoriasis**. Its therapeutic indications include: - **Psoriasis**: Calcipotriene is most commonly prescribed to treat **plaque psoriasis**, a condition characterized by the rapid buildup of skin cells that forms scaly, inflamed patches. It helps regulate skin cell production and reduces inflammation. - **Other Dermatoses**: While the main indication is psoriasis, **calcipotriene** may also be used off-label to treat other skin conditions related to abnormal cell turnover or inflammation, though its use for conditions other than psoriasis should be under the guidance of a healthcare provider.

Contra indication

**Calcipotriene 0.005%** is contraindicated in the following situations: - **Hypercalcemia**: Patients with **hypercalcemia** (elevated calcium levels in the blood) should not use Calcipotriene, as it may worsen the condition. - **Known Sensitivity**: If the patient has a known **allergy** to **calcipotriene** or any of the excipients in the formulation, it should not be used. Allergic reactions may include skin irritation, rash, or swelling. - **Pregnancy and Breastfeeding**: While **calcipotriene** can be used in some cases during pregnancy (category C), it is generally contraindicated on large body areas or for prolonged periods due to potential systemic absorption. A healthcare provider should be consulted before use in these cases.

Side Effect

While **Calcipotriene 0.005%** is generally well tolerated, some side effects may occur, including: - **Skin Irritation**: The most common side effect is **skin irritation** at the application site, which may manifest as redness, itching, or burning sensations. This usually resolves with continued use. - **Dry Skin**: Some individuals may experience **dryness** or **peeling** at the treated site, particularly if used for extended periods. - **Hypercalcemia**: Prolonged use or overuse of calcipotriene can lead to an elevated calcium level in the blood, resulting in symptoms such as **nausea**, **vomiting**, **muscle weakness**, **fatigue**, or **confusion**. - **Contact Dermatitis**: Although rare, some individuals may experience **contact dermatitis**, presenting as **redness** and **blisters** in response to the application of the cream or ointment. - **Photosensitivity**: Calcipotriene can cause **increased sensitivity to sunlight**, making the skin more prone to sunburn or irritation, so it’s important to avoid excessive sun exposure.

Pregnancy Category ID

3

Mode of Action

**Calcipotriene** is a synthetic **vitamin D3 analog** that works to regulate skin cell turnover and reduce inflammation. Its mechanism of action includes: - **Regulation of Keratinocyte Proliferation**: Calcipotriene binds to the **vitamin D receptor** on skin cells (keratinocytes) and modulates the production and differentiation of these cells, slowing the overproduction seen in **psoriasis**. - **Anti-inflammatory Effects**: Calcipotriene has anti-inflammatory properties, helping to reduce the swelling, redness, and itching commonly associated with conditions like **psoriasis**. - **Inhibition of T-cell Activation**: It inhibits the activation and proliferation of **T-cells** (a type of immune cell), which play a key role in the inflammatory process of **psoriasis**. This helps to reduce the immune system’s contribution to the skin condition.

Interaction

**Calcipotriene 0.005%** may have interactions with certain other medications and conditions: - **Topical Steroids**: When used in combination with **topical corticosteroids**, calcipotriene may enhance the effectiveness in treating psoriasis, but caution should be exercised to avoid potential **skin thinning** or other side effects from overuse of steroids. - **Systemic Vitamin D**: Concurrent use of **systemic vitamin D supplements** or other **vitamin D analogs** may increase the risk of **hypercalcemia**. Patients should inform their healthcare provider about all vitamin D-containing medications. - **Diuretics and Calcium**: Patients taking **thiazide diuretics** or other medications that affect calcium levels in the blood should be monitored for **hypercalcemia** when using **calcipotriene**.

Pregnancy Category Note

Information not available

Adult Dose

The typical adult dose of **Calcipotriene 0.005%** varies depending on the condition being treated, but general guidelines include: - **Psoriasis**: Apply a thin layer of **calcipotriene** to the affected area **once or twice daily**. It should not exceed **100 grams** per week in total to avoid potential toxicity or side effects like **hypercalcemia**. - **Treatment Duration**: The medication is usually applied for up to **2-4 weeks**, depending on the severity of the condition. Long-term use should be avoided unless otherwise directed by a healthcare provider. - **Combination with Other Treatments**: It may be used in combination with other topical treatments, such as corticosteroids, but should be done under medical supervision to avoid adverse effects.

Child Dose

For pediatric patients, **Calcipotriene 0.005%** should be used with caution: - **Children 2 years and older**: Apply a thin layer to the affected area **once daily**. The dose should not exceed **50 grams per week** in children to minimize the risk of **hypercalcemia**. - **Children under 2 years**: **Calcipotriene** is generally not recommended for children under the age of 2, as the safety and efficacy in this age group have not been established. For both pediatric and adult patients, the application of **calcipotriene** should be limited to the affected areas and should not cover large areas of skin, as this increases the potential for systemic absorption and adverse effects. Always follow the dosing instructions provided by the healthcare provider. In all cases, patients should consult their healthcare provider to determine the most appropriate dosage and duration of use for their specific condition.

Renal Dose

Since **Calcipotriene** is a topical treatment with minimal systemic absorption, **renal adjustments** are not typically necessary. However, patients with severe **renal impairment** or those who are at higher risk of **hypercalcemia** (such as those on dialysis) should be closely monitored while using **calcipotriene**. If there is any concern regarding systemic absorption, especially in patients with impaired kidney function, the dosage may need to be reduced, and healthcare provider consultation is essential.

Administration

Information not available